共 269 条
[1]
Furer V(2019)Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD RMD Open 5 751-762
[2]
Rondaan C(2021)Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry Rheumatol Int 41 e486-e492
[3]
Heijstek M(2013)Tuberculosis in anti-TNF-alpha treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population J Crohns Colitis 7 1884-1894
[4]
van Assen S(2009)Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry Arthritis Rheum 60 1185-1206
[5]
Bijl M(2010)The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement Eur Respir J 36 620-622
[6]
Agmon-Levin N(2007)Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy Swiss Med Wkly 137 247-253
[7]
Thiele F(2006)Tuberculosis in rheumatic patients treated with tumour necrosis factor alpha antagonists: the Portuguese experience Acta Reumatol Port 31 2122-2127
[8]
Klein A(2003)Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report Arthritis Rheum 48 1766-1772
[9]
Windschall D(2005)Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists Arthritis Rheum 52 36-45
[10]
Hospach A(2016)Consensus document on prevention and treatment of tuberculosis in patients for biological treatment Arch Bronconeumol 52 2102-2108